These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 23020725)

  • 21. Overcoming acquired resistance to kinase inhibition: the cases of EGFR, ALK and BRAF.
    Giroux S
    Bioorg Med Chem Lett; 2013 Jan; 23(2):394-401. PubMed ID: 23245516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cellular origins of drug resistance in cancer.
    Oxnard GR
    Nat Med; 2016 Mar; 22(3):232-4. PubMed ID: 26937615
    [No Abstract]   [Full Text] [Related]  

  • 23. EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head.
    Clark J; Cools J; Gilliland DG
    PLoS Med; 2005 Mar; 2(3):e75. PubMed ID: 15736989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!
    Codacci-Pisanelli G; Frati L; Mini E
    J Chemother; 2011 Aug; 23(4):245-6. PubMed ID: 21803707
    [No Abstract]   [Full Text] [Related]  

  • 25. New and emerging targeted treatments in advanced non-small-cell lung cancer.
    Hirsch FR; Suda K; Wiens J; Bunn PA
    Lancet; 2016 Sep; 388(10048):1012-24. PubMed ID: 27598681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer.
    Al Olayan A; Al Hussaini H; Jazieh AR
    J Infect Public Health; 2012 Dec; 5 Suppl 1():S50-60. PubMed ID: 23244189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acquired resistance mechanisms to EGFR-TKIs in EGFR mutated lung cancers].
    Suda K; Mitsudomi T
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():341-5. PubMed ID: 23513863
    [No Abstract]   [Full Text] [Related]  

  • 28. Lung cancer in the era of targeted therapy: a cytologist's perspective.
    Zakowski MF
    Arch Pathol Lab Med; 2013 Dec; 137(12):1816-21. PubMed ID: 23597048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer.
    Han F; He J; Li F; Yang J; Wei J; Cho WC; Liu X
    Biomed Res Int; 2015; 2015():672759. PubMed ID: 26273639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successes and limitations of targeted cancer therapy in lung cancer.
    Suda K; Mitsudomi T
    Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discussion - EGFR-targeted agents.
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S150-1. PubMed ID: 18520301
    [No Abstract]   [Full Text] [Related]  

  • 32. Update on HER1-3 in advanced non-small-cell lung cancer.
    Horn L; Lovly C
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S369-71. PubMed ID: 23160321
    [No Abstract]   [Full Text] [Related]  

  • 33. Overcoming resistance to targeted therapy for lung cancer.
    Govindan R
    N Engl J Med; 2015 Apr; 372(18):1760-1. PubMed ID: 25923556
    [No Abstract]   [Full Text] [Related]  

  • 34. [Molecular targeted therapies and cytotoxics: Friends or foes?].
    Vignot S; Zalcman G
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S91-2. PubMed ID: 26118883
    [No Abstract]   [Full Text] [Related]  

  • 35. [Improving the internal medical care to set up a leading model for precision medicine development in lung cancer].
    Han BH
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):81-85. PubMed ID: 28219199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists.
    O'Neill AC; Jagannathan JP; Ramaiya NH
    Korean J Radiol; 2017; 18(1):6-17. PubMed ID: 28096714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases.
    Pallan L; Taniere P; Koh P
    J Thorac Oncol; 2014 Oct; 9(10):e75. PubMed ID: 25521406
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer.
    Liu WJ; Du Y; Wen R; Yang M; Xu J
    Pharmacol Ther; 2020 Feb; 206():107438. PubMed ID: 31715289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What can be done for patients with NSCLC without druggable targets?
    Besse B; Andre F; Soria JC
    Lancet Oncol; 2013 Mar; 14(3):191-2. PubMed ID: 23452354
    [No Abstract]   [Full Text] [Related]  

  • 40. From mice to men: GEMMs as trial patients for new NSCLC therapies.
    Hayes SA; Hudson AL; Clarke SJ; Molloy MP; Howell VM
    Semin Cell Dev Biol; 2014 Mar; 27():118-27. PubMed ID: 24718320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.